Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
21 July 2023Website:
http://turnstonebio.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 04 Oct 2024 23:38:43 GMTDividend
Analysts recommendations
Institutional Ownership
TSBX Latest News
Announced positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer including a complete response in one of the four patients reported Cash position expected to fund operations into 3Q 2025 SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the second quarter ended June 30, 2024, and provided recent business highlights. “We have continued to bolster our position by making advances across our pipeline and corporate operations in the second quarter of 2024.
On July 25, 2023, FMR LLC (Trades, Portfolio), a renowned investment firm, made a significant move in the biotechnology sector by acquiring a substantial stake in Turnstone Biologics Corp ( TSBX , Financial). This article provides an in-depth analysis of the transaction, profiles of both FMR LLC (Trades, Portfolio) and Turnstone Biologics Corp, and the potential implications of this acquisition on the market.
Turnstone Biologics Corp. TSBX, is headed for its public debut Friday, as the San Diego-based biotechnology company focused on treating tumors raised $80 million through an upsized initial public offering. The company said it sold 6.67 million shares in the IPO, up from a previously expected offering of 5.80 million shares.
Turnstone Biologics Corp. has filed proposed terms for a $75.4 million IPO. The firm is developing drug treatment candidates for solid tumors and other cancer conditions. Turnstone Biologics' major partners have terminated their collaboration agreements, so I'm cautious about the firm's prospects.
Turnstone Biologics TSBX, , a clinical-stage biotech that specializes in treatments for solid tumors, set terms for its initial public offering on Monday with plans to offer 5.8 million shares priced at $12 to $14 each. The company would raise $81.2 million at the top of that range at a valuation of $298 million.
What type of business is Turnstone Biologics?
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
What sector is Turnstone Biologics in?
Turnstone Biologics is in the Healthcare sector
What industry is Turnstone Biologics in?
Turnstone Biologics is in the Biotechnology industry
What country is Turnstone Biologics from?
Turnstone Biologics is headquartered in United States
When did Turnstone Biologics go public?
Turnstone Biologics initial public offering (IPO) was on 21 July 2023
What is Turnstone Biologics website?
https://turnstonebio.com
Is Turnstone Biologics in the S&P 500?
No, Turnstone Biologics is not included in the S&P 500 index
Is Turnstone Biologics in the NASDAQ 100?
No, Turnstone Biologics is not included in the NASDAQ 100 index
Is Turnstone Biologics in the Dow Jones?
No, Turnstone Biologics is not included in the Dow Jones index
When was Turnstone Biologics the previous earnings report?
No data
When does Turnstone Biologics earnings report?
The next expected earnings date for Turnstone Biologics is 08 November 2024